RTP Mobile Logo
Meet The Professors: Management of Multiple Myeloma (Audio Program)
Released April 2021

Featuring a roundtable discussion with Drs Sergio A Giralt, Jonathan L Kaufman and Peter Voorhees. (Audio Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for medical oncologists, hematologists and other healthcare providers involved in the treatment of multiple myeloma (MM).

    OVERVIEW OF ACTIVITY
    MM is a plasma cell neoplasm that accounts for approximately 19% of all hematologic cancer and carries one of the worst ratios of death to new cases. Although MM represents only 1.8% of all cancer cases diagnosed annually in the United States, practicing clinicians would be hard pressed to identify another area of oncology in which the research database and related treatment implications have evolved more rapidly over the past decade. Research findings with several recently approved therapies and their introduction into the treatment of MM necessitate rapid and consistent access to learning opportunities for clinicians who care for these patients.

    To address that need this CME activity, which is conducted in partnership with the University of South Florida (USF Health) Office of Continuing Professional Development, features investigator perspectives on existing and emerging research surrounding the care of patients with MM. By providing access to the latest therapeutic developments and expert perspectives on the disease, this program will assist medical oncologists, hematologists and other community-based clinicians in the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Design and implement a plan of care for patients with newly diagnosed or relapsed/refractory (R/R) multiple myeloma (MM), considering the applicability of existing and emerging clinical trial data.
    • Discuss research data informing the use of monoclonal antibody therapy directed at CD38 for patients with MM, and discern how this strategy can be effectively integrated into clinical management.
    • Appraise recent data with the FDA-approved agent belantamab mafodotin for R/R MM, and identify patients for whom this treatment may be appropriate.
    • Explore available data documenting the activity of chimeric antigen receptor T-cell therapy and bispecific T-cell engagers, and use this knowledge to identify patients with MM who may be appropriate for these therapeutic approaches on or outside of clinical trial protocols.
    • Recognize treatment-related adverse events associated with newly approved agents in patients with R/R MM, and offer supportive strategies to minimize and manage these toxicities.

    CONTACT INFORMATION
    If you have questions regarding credit, please contact cpdsupport@usf.edu.

    ACCREDITATION STATEMENT
    USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Audio Program: USF Health designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Video Program: USF Health designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of these CME activities, which includes participation in the evaluation components, enables the participant to earn up to 1.75 (audio) and 1.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.

    For ABIM MOC points, your information will be shared with the ABIM through USF Health's ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for MOC points to appear on your ABIM records.

    Personal information and data sharing: Research To Practice and USF Health aggregate deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/MTPMM21/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/MTPMM21/Video.

    Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/MTPMM21/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/MTPMM21.

    POTENTIAL CONFLICTS OF INTEREST
    USF Health and Research To Practice adhere to The Standards for Integrity and Independence in Accredited Continuing Education in all of its continuing professional development activities. It is USF Health’s and Research To Practice’s policy that all persons in a position to influence content in this activity disclose any financial relationship with an ineligible organization. USF Health and Research To Practice have mitigated all conflicts of interest.

    FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:

    Presenting Faculty Members

    Sergio A Giralt, MD
    Deputy Division Head of Hematologic Malignancies
    Melvin Berlin Family Chair in Myeloma Research
    Memorial Sloan Kettering Cancer Center
    Professor of Medicine, Weill Cornell Medical College
    New York, New York

    Scientific Advisory Board: Actinium Pharmaceuticals Inc, Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Omeros, Pfizer Inc, Sanofi Genzyme; Research Support: Actinium Pharmaceuticals Inc, Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Pfizer Inc, Sanofi Genzyme.

    Jonathan L Kaufman, MD
    Associate Professor of Hematology and Medical Oncology
    Winship Cancer Institute of Emory University
    Atlanta, Georgia

    Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group; Data and Safety Monitoring Board/Committee: TG Therapeutics Inc.

    Peter Voorhees, MD
    Professor of Medicine
    Member, Plasma Cell Disorders Division
    Levine Cancer Institute, Atrium Health
    Charlotte, North Carolina

    Advisory Committee: AbbVie Inc, Bristol-Myers Squibb Company; Consulting Agreements: GlaxoSmithKline, Novartis, Oncopeptides; Data and Safety Monitoring Board/Committee: Bristol-Myers Squibb Company.

    Contributing General Medical Oncologists

    Lyle Feinstein, MD
    Attending Physician, Malignant Hematology and Bone Marrow Transplant
    Miami Cancer Institute
    Miami, Florida

    No financial interests or affiliations to disclose.

    Ranju Gupta, MD
    Attending Physician
    Co-Director, Cardio-Oncology Program
    LVPG Hematology Oncology Associates
    Lehigh Valley Health Network
    Bethlehem, Pennsylvania

    Speakers Bureau: Lilly.

    Neil Morganstein, MD
    Hematology Oncology
    Atlantic Health System
    Summit, New Jersey

    No financial interests or affiliations to disclose.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company and Verastem Inc.

    USF HEALTH CPD STAFF AND RESEARCH TO PRACTICE CME PLANNING COMMITTEE — Members, Staff, and Reviewers have no relevant conflicts to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. USF Health and Research To Practice do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Adaptive Biotechnologies Corporation, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Takeda Oncology.

    Release date: April 2021
    Expiration date: April 2022

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):